Marlon Byrd’s late-career revival was shattered by two positive tests for performance-enhancing drugs. After his 2011 season with the Chicago Cubs, Byrd was traded to the Boston Red Sox in April 2012, but he was designated for assignment in June and released shortly afterward. On June 25, 2012, Major League Baseball suspended him for 50 games after a positive test for a banned substance. Byrd was placed on the restricted list and remained unavailable until August 20, losing valuable playing time during a season in which his career was already beginning to unravel. Rather than ending his career, however, the suspension was followed by a surprising comeback: he signed with the New York Mets in 2013, revived his production, earned a trade to the Pittsburgh Pirates, and helped them reach the postseason before returning to the Phillies on a substantial two-year contract.
The second violation proved far more devastating. After joining the Cleveland Indians in 2016, Byrd appeared in 34 games and was hitting .270 with five home runs and 19 RBIs before MLB announced on June 1 that he had received a 162-game suspension for a second positive PED test. Under baseball’s disciplinary system, the repeat offense effectively ended his career. Byrd told his teammates on the day the suspension began that he was finished, bringing an abrupt conclusion to a career that had included a 2010 All-Star selection, a dramatic post-suspension resurgence, and several lucrative contracts. The episode became a stark example of how a player could rebuild his reputation after an initial doping ban, only to lose his career entirely after a second violation.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.